Vancomycin Hydrochloride for Injection Product Launches

Article

The product has an estimated market size of $338M for the 12 months ending August 2018 according to IQVIA.

Officials with Xellia Pharmaceuticals (‘Xellia’) announced they have launched Vancomycin Hydrochloride for Injection, USP within the United States market.

The product has an estimated market size of $338M for the 12 months ending August 2018 according to IQVIA.

“Today marks an important milestone for our US market strategy and represents a significant step forward in the company's evolution as we bring the first product to the US market under the Xellia brand,” Carl-Aake Carlsson, Xellia’s CEO, said in a prepared statement about the launch.

Full prescribing information for Vancomycin Hydrochloride for Injection, USP can be found at www.xellia.com/us.

Related Videos
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Andrea Izzotti
Inflation Reduction Act is shown using the text and the US flag - Image credit: Andrii | stock.adobe.com
Pharmacy Interior | Image Credit: Tyler Olson - stock.adobe.com
Male pharmacist selling medications at drugstore to a senior woman customer | Image Credit: Zamrznuti tonovi - stock.adobe.com
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen | stock.adobe.com
Pharmacy, medicine and senior woman consulting pharmacist on prescription. Healthcare, shopping and elderly female in consultation with medical worker for medication box, pills or product in store - Image credit: C Daniels/peopleimages.com | stock.adobe.com
Image credit: fidaolga - stock.adobe.com
Pharmacists checking inventory at hospital pharmacy- Image credit: Jacob Lund | stock.adobe.com
Young male pharmacist giving prescription medications to senior female customer in a pharmacy | Image Credit: Zamrznuti tonovi - stock.adobe.com
© 2023 MJH Life Sciences

All rights reserved.